GlassScriptPhysician profile
Kaitlyn Steffensmeier
NPI 1659875888
$809.63
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $499 · 2023: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $152.54 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $62.33 | 2022-2023 | Jardiance, Emgality, Mounjaro |
| Merck Sharp & Dohme LLC | $60.34 | 2021-2022 | |
| Amarin Pharma, INC. | $59.80 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.85 | 2021-2022 | |
| Abbvie INC. | $48.79 | 2023 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $39.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.80 | 2022-2023 | Xifaxan |
| Corium, LLC | $34.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.75 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.61 | 2021-2022 | |
| Exact Sciences Corporation | $19.49 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $18.12 | 2022 | |
| Dexcom, INC. | $16.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.89 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $15.51 | 2023 | Heplisav-B |
| Renalytix Ai, INC. | $15.49 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Jazz Pharmaceuticals INC. | $14.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.04 | 2022 | |
| Bausch Health US, LLC | $12.56 | 2022 | |
| Nabriva Therapeutics, Plc | $12.13 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Steffensmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.